Published in Biotech Business Week, April 26th, 2004
The acquisition of Dharmacon enhances Fisher's position in the rapidly growing life science market and further expands the company's product portfolio.
Dharmacon is focused on RNA interference (RNAi) technology.
Fisher Scientific International, Inc., offers more than 600,000 products and services to more than 350,000 customers located in approximately 145 countries. Fisher's customers include pharmaceutical and biotech companies; colleges and universities; medical-research institutions; hospitals...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.